• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.200 +0.110 (+2.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,227,229
Open 4.170
Bid (Size) 4.220 (3,500)
Ask (Size) 4.230 (1,200)
Prev. Close 4.090
Today's Range 4.120 - 4.230
52wk Range 3.790 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
January 01, 2026
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
January 01, 2026
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model... 
Via TokenRing AI
Topics Artificial Intelligence

Performance

YTD
N/A
N/A
1 Month
-14.6%
-14.6%
3 Month
-24.1%
-24.1%
6 Month
-14.8%
-14.8%
1 Year
-46.2%
-46.2%

More News

Read More
News headline image
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗
January 01, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood’s Strategic Pivot: Ark Invest Trims Tesla Holdings to Fuel AI and Crypto Bets Ahead of 2026
December 25, 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
December 17, 2025
Via AB Newswire
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗
December 17, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why ↗
December 17, 2025
Via Benzinga
News headline image
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today ↗
December 17, 2025
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Why Recursion Pharamaceuticals Topped the Market Today ↗
December 08, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
December 08, 2025
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer: This Health Care Stock Has Been 'Horrendous' ↗
December 05, 2025
Via Benzinga
News headline image
10 AI Stocks Worth Buying Right Now ↗
December 04, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
December 03, 2025
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
December 01, 2025
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
December 01, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
popEVE AI: Harvard-Developed Model Set to Revolutionize Rare Disease Diagnosis and Drug Discovery
November 25, 2025
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗
November 24, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Recursion Pharmaceuticals a Meme Stock? ↗
November 19, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
November 14, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
Via FinancialNewsMedia
News headline image
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock ↗
November 12, 2025
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
November 06, 2025
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Nvidia's AI Reign: A $5 Trillion Bellwether Shaping Wall Street's Fortunes
November 11, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Law Enforcement
News headline image
Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway ↗
November 05, 2025
Via Chartmill

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.200
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 707.39M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 707M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap